Oculis Holding AG (ICE:OCS)
Iceland · Delayed Price · Currency is ISK | Market Cap | 227.34B +80.8% |
| Revenue (ttm) | 174.30M +49.9% |
| Net Income | -14.68B |
| EPS | -267.30 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 71,690 |
| Average Volume | 55,389 |
| Open | 3,490.00 |
| Previous Close | 3,440.00 |
| Day's Range | 3,490.00 - 3,750.00 |
| 52-Week Range | 1,965.00 - 4,180.00 |
| Beta | 0.20 |
| RSI | 57.32 |
| Earnings Date | May 7, 2026 |
About Oculis Holding AG
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological da... [Read more]
Financial Performance
In 2025, Oculis Holding AG's revenue was 1.20 million, an increase of 74.78% compared to the previous year's 686,000. Losses were -98.96 million, 15.4% more than in 2024.
Financial numbers in CHF Financial StatementsNews
Oculis initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Oculis (OCS) with a Buy rating and $75 price target The firm sees OCS-01 having the potential to become the first non-invasive topical treatment for DME,…
Oculis price target raised to $42 from $38 at JPMorgan
JPMorgan raised the firm’s price target on Oculis (OCS) to $42 from $38 and keeps an Overweight rating on the shares. The firm expects topline results in a joint disclosure…
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
ZUG, Switzerland, May 15, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company, the annual equity incentive a...
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
ZUG, Switzerland, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2026 Annual General Meeting held on May...
Oculis Holding AG Transcript: AGM 2026
The meeting approved all agenda items, including financial statements, board elections, compensation, and capital increases. Clinical programs advanced significantly, with major trial readouts expected in 2026 and 2027. Net loss increased due to R&D investment.
Oculis Holding AG Slides: FY 2026
Oculis Holding AG has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 13, 2026.
Oculis price target raised to $47 from $44 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Oculis (OCS) to $47 from $44 and keeps a Buy rating on the shares. Oculis reported Q1 results and completed Phase 3…
Oculis price target raised to $44 from $43 at BofA
BofA raised the firm’s price target on Oculis (OCS) to $44 from $43 and keeps a Buy rating on the shares following the company’s Q1 update.
Oculis reports Q1 EPS (49c), consensus (41c)
Riad Sherif, Chief Executive Officer of Oculis (OCS), stated, “We began 2026 with strong execution momentum across our late-stage clinical trials. We are positioned for a pivotal year, with key…
Oculis Reports Q1 2026 Financial Results and Provides Company Update
ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pipeline Advancing as Planned, Leading with OCS-01 Key Milestone Completion of LPLV in Both DIAMOND Phase 3 Trials; Data Readout on Track for June 20...
Oculis Holding AG Earnings release: Q1 2026
Oculis Holding AG released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
ZUG, Switzerland, May 7 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical need...
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular edema (DME) management Oculis is on track to report top...
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
ZUG, Switzerland, May 01, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant u...
Oculis Publishes Invitation to the Annual General Meeting
ZUG, Switzerland, April 21, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), today published the invitation to the 2026 Annual General Meeting, which will be held on May...
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant...
Oculis Holding AG Transcript: 25th Annual Needham Virtual Healthcare Conference
Three late-stage assets are advancing in large ophthalmic and neuro-ophthalmic markets, with OCS-01 phase III results expected in June, licaminlimab targeting a genotype-defined dry eye population, and privosegtor in registrational trials for rare optic neuropathies. Strong financials and regulatory support position the pipeline for multiple milestones through 2027.
Oculis to Participate in Upcoming Investor Conferences
ZUG, Switzerland, April 07, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophtha...
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
ZUG, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant...
Three new option listings on March 17th
New option listings for March 17th include GBank Financial Holdings Inc (GBFH), Oculis Holding AG (OCS), and Sionna Therapeutics Inc (SION).
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
ZUG, Switzerland, 16 March, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical ne...
Oculis Holding AG Transcript: Leerink Global Healthcare Conference 2026
Three phase III programs are advancing, with a topical DME therapy nearing pivotal data and a biomarker-driven dry eye trial set for Q4 results. Neuroprotection candidate Privosegtor shows strong efficacy in optic neuritis, with premium pricing anticipated.
Oculis price target raised to $50 from $40 at Stifel
Stifel raised the firm’s price target on Oculis (OCS) to $50 from $40 and keeps a Buy rating on the shares after having hosted management on the road. The company…
Oculis Publishes 2025 Consolidated Financial Statements
ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Following the Company‘s press release published on March 3, the audited consolidated financial statements for the financial year 2025 and the MD&A,...
Oculis files automatic mixed securities shelf
16:21 EST Oculis (OCS) files automatic mixed securities shelf